Thanks to a systems biology approach, the researchers constructed and validated a model of the neuronal molecular regulatory network for AD that is a proof-of-principle screening of drugs that directly target AD-relevant cellular pathways and induce a reduction in Aβ and p-tau [85]. This evidence concerns the gene MAPT and Alzheimer disease.